762 related articles for article (PubMed ID: 24934793)
1. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
Chiarelli AM; Prummel MV; Muradali D; Majpruz V; Horgan M; Carroll JC; Eisen A; Meschino WS; Shumak RS; Warner E; Rabeneck L
J Clin Oncol; 2014 Jul; 32(21):2224-30. PubMed ID: 24934793
[TBL] [Abstract][Full Text] [Related]
2. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
[TBL] [Abstract][Full Text] [Related]
3. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
5. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
Kriege M; Brekelmans CT; Boetes C; Muller SH; Zonderland HM; Obdeijn IM; Manoliu RA; Kok T; Rutgers EJ; de Koning HJ; Klijn JG;
Cancer; 2006 Jun; 106(11):2318-26. PubMed ID: 16615112
[TBL] [Abstract][Full Text] [Related]
6. MRI screening in a clinic population with a family history of breast cancer.
Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
[TBL] [Abstract][Full Text] [Related]
7. Five-year analysis of magnetic resonance imaging as a screening tool in women at hereditary risk of breast cancer.
Kam JK; Naidu P; Rose AK; Mann GB
J Med Imaging Radiat Oncol; 2013 Aug; 57(4):400-6. PubMed ID: 23870334
[TBL] [Abstract][Full Text] [Related]
8. Breast MRI: opportunities and challenges.
Day D
Minn Med; 2009 Dec; 92(12):45-8. PubMed ID: 20092173
[TBL] [Abstract][Full Text] [Related]
9. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Leach MO; Boggis CR; Dixon AK; Easton DF; Eeles RA; Evans DG; Gilbert FJ; Griebsch I; Hoff RJ; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Thompson D; Warren RM;
Lancet; 2005 May 21-27; 365(9473):1769-78. PubMed ID: 15910949
[TBL] [Abstract][Full Text] [Related]
10. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.
Lehman CD; Blume JD; Weatherall P; Thickman D; Hylton N; Warner E; Pisano E; Schnitt SJ; Gatsonis C; Schnall M; DeAngelis GA; Stomper P; Rosen EL; O'Loughlin M; Harms S; Bluemke DA;
Cancer; 2005 May; 103(9):1898-905. PubMed ID: 15800894
[TBL] [Abstract][Full Text] [Related]
11. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation.
Al-Hallaq HA; Mell LK; Bradley JA; Chen LF; Ali AN; Weichselbaum RR; Newstead GM; Chmura SJ
Cancer; 2008 Nov; 113(9):2408-14. PubMed ID: 18823018
[TBL] [Abstract][Full Text] [Related]
13. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
[TBL] [Abstract][Full Text] [Related]
14. Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study.
Warner E; Causer PA; Wong JW; Wright FC; Jong RA; Hill KA; Messner SJ; Yaffe MJ; Narod SA; Plewes DB
Breast J; 2011; 17(1):9-17. PubMed ID: 21251121
[TBL] [Abstract][Full Text] [Related]
15. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
[TBL] [Abstract][Full Text] [Related]
16. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.
Kuhl CK; Schrading S; Leutner CC; Morakkabati-Spitz N; Wardelmann E; Fimmers R; Kuhn W; Schild HH
J Clin Oncol; 2005 Nov; 23(33):8469-76. PubMed ID: 16293877
[TBL] [Abstract][Full Text] [Related]
17. Mammographic, US, and MR imaging phenotypes of familial breast cancer.
Schrading S; Kuhl CK
Radiology; 2008 Jan; 246(1):58-70. PubMed ID: 18096529
[TBL] [Abstract][Full Text] [Related]
18. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
[TBL] [Abstract][Full Text] [Related]
20. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.
Kuhl C; Weigel S; Schrading S; Arand B; Bieling H; König R; Tombach B; Leutner C; Rieber-Brambs A; Nordhoff D; Heindel W; Reiser M; Schild HH
J Clin Oncol; 2010 Mar; 28(9):1450-7. PubMed ID: 20177029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
